Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| UG3HD096915 | U.S. NIH Grant/Contract | View source | |
| UH3HD096915 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | NIH |
| Infectious Diseases Research Collaboration, Uganda | OTHER |
| Kenya Medical Research Institute | OTHER |
Not provided
Not provided
Not provided
Not provided
The goal of this study is to evaluate the effect of a combination intervention on long-term HIV viral load (VL) suppression among HIV-infected adolescents and young adults 15-24 years of age. The study will take place in 28 rural HIV clinics in western Kenya and southwest Uganda. Clinics will be randomly chosen to either continue to provide study participants standard care or to provide the study intervention, which consists of discussion and counseling on major issues or life events, flexible access to the clinic, and rapid turnaround of VL test results. Participants will take part in the study for at least 2 years.
The randomized controlled trial (RCT) will evaluate the effect of the SEARCH Youth intervention on long-term HIV viral load suppression among HIV-infected adolescents/young adults. The study's intervention is based on the PRECEDE model of behavioral change that is targeted towards adolescent and young adult behavior. The study design is a cluster-randomized trial where the unit of randomization is the HIV clinic: 14 clinics randomized to the intervention and 14 to the optimized country standard of care (Differentiated ART care, standard clinic hours, routine VL monitoring, access to 2nd and 3rd line ART), balanced within country. The target enrollment for the intervention is approximately 2300 (50-100 adolescents/young adults with HIV in each clinic, plus family members, providers and others taking part in qualitative interviews).
Community-tailored youth testing and linkage strategies for ART will be implemented to recruit youth for the SEARCH Youth combination intervention RCT. Strategies to reach youth at the highest risk of HIV infection will be implemented. Those individuals who test HIV-positive will be referred to the local clinic for HIV treatment services and, if they otherwise meet entry criteria, to the SEARCH Youth study for possible inclusion.
The components of the SEARCH Youth intervention include:
Participants will take part in the study for at least 2 years.
Some participants, family members, providers, HIV-negative youth and key informants will also take part in qualitative interview guides. Costs of the SEARCH Youth intervention will be evaluated to assess its efficiency and cost-effectiveness including as cost per participant, cost per additional participant with viral suppression and cost per DALY gained.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention Clinics | Experimental | SEARCH Youth combination intervention, which includes life-stage assessment and counseling, rapid VL feedback, structured choice clinic access, and e-collaboratives chat-based discussion among providers |
|
| Control Clinics | No Intervention | Optimized country standard of care |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SEARCH Youth combination intervention | Other |
|
| Measure | Description | Time Frame |
|---|---|---|
| Effectiveness of SEARCH Youth Intervention | Percentage of study participants with virologic suppression (HIV RNA <400 c/mL) at 2 years of follow-up. Mean was calculated as the average percentage across the clusters (clinics) | 2 years |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Diane V Havlir, MD | University of California, San Francisco | Principal Investigator |
| Moses R Kamya, MBChB, MMed, PhD | Makerere University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Western Kenya | Sindo | Kenya | ||||
| Southwestern Uganda |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24076661 | Background | Lamb MR, Fayorsey R, Nuwagaba-Biribonwoha H, Viola V, Mutabazi V, Alwar T, Casalini C, Elul B. High attrition before and after ART initiation among youth (15-24 years of age) enrolled in HIV care. AIDS. 2014 Feb 20;28(4):559-68. doi: 10.1097/QAD.0000000000000054. | |
| 23373540 | Background | Evans D, Menezes C, Mahomed K, Macdonald P, Untiedt S, Levin L, Jaffray I, Bhana N, Firnhaber C, Maskew M. Treatment outcomes of HIV-infected adolescents attending public-sector HIV clinics across Gauteng and Mpumalanga, South Africa. AIDS Res Hum Retroviruses. 2013 Jun;29(6):892-900. doi: 10.1089/AID.2012.0215. Epub 2013 Feb 25. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Intervention Clinics | SEARCH Youth combination intervention, which includes life-stage assessment and counseling, rapid VL feedback, structured choice clinic access, and e-collaboratives chat-based discussion among providers SEARCH Youth combination intervention:
|
| FG001 | Control Clinics | Optimized country standard of care |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Population includes participants who were included in the primary analysis, enrolled before December 1, 2019.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Intervention Clinics | SEARCH Youth combination intervention, which includes life-stage assessment and counseling, rapid VL feedback, structured choice clinic access, and e-collaboratives chat-based discussion among providers SEARCH Youth combination intervention:
Information presented for participants included in primary analysis. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Median |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Effectiveness of SEARCH Youth Intervention | Percentage of study participants with virologic suppression (HIV RNA <400 c/mL) at 2 years of follow-up. Mean was calculated as the average percentage across the clusters (clinics) | Study participants at year 2, excluding those who enrolled on/after Dec 1, 2019, transferred care, outmigrated, or withdrew. | Posted | Mean | 95% Confidence Interval | % of participants | 2 years | Clinics | Clinics |
|
2 years
Non-fatal serious adverse events were reported regardless of relationship to the study intervention in the intervention arm only. Control arm participants were not contacted during the study except at baseline and endpoint. Other [Not Including Serious] Adverse Events were not monitored/assessed in both intervention and control arms. Fatal serious adverse events were reported in both the intervention arm and the control arm regardless of relationship.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Intervention Clinics | SEARCH Youth combination intervention, which includes life-stage assessment and counseling, rapid VL feedback, structured choice clinic access, and e-collaboratives chat-based discussion among providers SEARCH Youth combination intervention:
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Dehydration | Metabolism and nutrition disorders | Non-systematic Assessment | Serious Adverse Events not resulting in death were not monitored/assessed in the control arm. |
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Douglas Black | University of California, San Francisco | 4158063016 | douglas.black@ucsf.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Oct 27, 2022 | Jun 21, 2024 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Nov 4, 2022 | Jun 21, 2024 | SAP_001.pdf |
| ICF | No | No | Yes | Informed Consent Form | Nov 21, 2019 | Sep 17, 2024 | ICF_002.pdf |
Not provided
| Makerere University | OTHER |
Cluster-randomized trial
Not provided
Not provided
Not provided
Not provided
| Mbarara |
| Uganda |
| 19282780 | Background | Nachega JB, Hislop M, Nguyen H, Dowdy DW, Chaisson RE, Regensberg L, Cotton M, Maartens G. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr. 2009 May 1;51(1):65-71. doi: 10.1097/QAI.0b013e318199072e. |
| 25695494 | Background | Jobanputra K, Parker LA, Azih C, Okello V, Maphalala G, Kershberger B, Khogali M, Lujan J, Antierens A, Teck R, Ellman T, Kosgei R, Reid T. Factors associated with virological failure and suppression after enhanced adherence counselling, in children, adolescents and adults on antiretroviral therapy for HIV in Swaziland. PLoS One. 2015 Feb 19;10(2):e0116144. doi: 10.1371/journal.pone.0116144. eCollection 2015. |
| 28102610 | Background | Zurcher K, Mooser A, Anderegg N, Tymejczyk O, Couvillon MJ, Nash D, Egger M; IeDEA and MESH consortia. Outcomes of HIV-positive patients lost to follow-up in African treatment programmes. Trop Med Int Health. 2017 Apr;22(4):375-387. doi: 10.1111/tmi.12843. Epub 2017 Feb 20. |
| 19298993 | Background | Massaquoi M, Zachariah R, Manzi M, Pasulani O, Misindi D, Mwagomba B, Bauernfeind A, Harries AD. Patient retention and attrition on antiretroviral treatment at district level in rural Malawi. Trans R Soc Trop Med Hyg. 2009 Jun;103(6):594-600. doi: 10.1016/j.trstmh.2009.02.012. Epub 2009 Mar 18. |
| 37541706 | Derived | Ruel T, Mwangwa F, Balzer LB, Ayieko J, Nyabuti M, Mugoma WE, Kabami J, Kamugisha B, Black D, Nzarubara B, Opel F, Schrom J, Agengo G, Nakigudde J, Atuhaire HN, Schwab J, Peng J, Camlin C, Shade SB, Bukusi E, Kapogiannis BG, Charlebois E, Kamya MR, Havlir D. A multilevel health system intervention for virological suppression in adolescents and young adults living with HIV in rural Kenya and Uganda (SEARCH-Youth): a cluster randomised trial. Lancet HIV. 2023 Aug;10(8):e518-e527. doi: 10.1016/S2352-3018(23)00118-2. |
| 35818888 | Derived | Johnson-Peretz J, Lebu S, Akatukwasa C, Getahun M, Ruel T, Lee J, Ayieko J, Mwangwa F, Owino L, Onyango A, Maeri I, Atwine F, Charlebois ED, Bukusi EA, Kamya MR, Havlir DV, Camlin CS. "I was still very young": agency, stigma and HIV care strategies at school, baseline results of a qualitative study among youth in rural Kenya and Uganda. J Int AIDS Soc. 2022 Jul;25 Suppl 1(Suppl 1):e25919. doi: 10.1002/jia2.25919. |
| 35578398 | Derived | Mwangwa F, Charlebois ED, Ayieko J, Olio W, Black D, Peng J, Kwarisiima D, Kabami J, Balzer LB, Petersen ML, Kapogiannis B, Kamya MR, Havlir DV, Ruel TD. Two or more significant life-events in 6-months are associated with lower rates of HIV treatment and virologic suppression among youth with HIV in Uganda and Kenya. AIDS Care. 2023 Jan;35(1):95-105. doi: 10.1080/09540121.2022.2052260. Epub 2022 May 16. |
| Transfered to non-study clinic |
|
| Withdrawal by Subject |
|
| BG001 | Control Clinics | Optimized country standard of care. Information presented for participants included in primary analysis. |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Education (started or completed) | Count of Participants | Participants |
|
| Employment status | Count of Participants | Participants |
|
| Marital status | Count of Participants | Participants |
|
| Number of children | Count of Participants | Participants |
|
| Drinks alcohol | Count of Participants | Participants |
|
| Mobile | Lived away from home for more than 1 month in the previous 6 months. | Count of Participants | Participants |
|
| Antiretroviral regimen at enrolment | Data missing from 16 participants - 7 in intervention group, 9 in control group | Count of Participants | Participants |
|
| Baseline viral load <400 copies per mL | Data missing from 16 participants: 5 intervention participants, 11 control participants | Count of Participants | Participants |
|
| Baseline care status | Data missing for 2 participants, 1 intervention participant, 1 control participant | Count of Participants | Participants |
|
| OG001 | Control Clinics | Optimized country standard of care |
|
|
|
| 16 |
| 1,012 |
| 48 |
| 1,012 |
| 0 |
| 0 |
| EG001 | Control Clinics | Optimized country standard of care | 13 | 976 | 13 | 976 | 0 | 0 |
|
| Urinary tract infection | Infections and infestations | Non-systematic Assessment | Serious Adverse Events not resulting in death were not monitored/assessed in the control arm. |
|
| Hernia | Gastrointestinal disorders | Non-systematic Assessment | Serious Adverse Events not resulting in death were not monitored/assessed in the control arm. |
|
| Malaria | Infections and infestations | Non-systematic Assessment | Serious Adverse Events not resulting in death were not monitored/assessed in the control arm. |
|
| Depression | Psychiatric disorders | Non-systematic Assessment | Serious Adverse Events not resulting in death were not monitored/assessed in the control arm. |
|
| Pneumonia | Infections and infestations | Non-systematic Assessment | Serious Adverse Events not resulting in death were not monitored/assessed in the control arm. |
|
| Oral thrush | Infections and infestations | Non-systematic Assessment | Serious Adverse Events not resulting in death were not monitored/assessed in the control arm. |
|
| Abdominal distension | Gastrointestinal disorders | Non-systematic Assessment | Serious Adverse Events not resulting in death were not monitored/assessed in the control arm. |
|
| Spontaneous abortion | Pregnancy, puerperium and perinatal conditions | Non-systematic Assessment | Serious Adverse Events not resulting in death were not monitored/assessed in the control arm. |
|
| Injury | Musculoskeletal and connective tissue disorders | Non-systematic Assessment | Serious Adverse Events not resulting in death were not monitored/assessed in the control arm. |
|
| Cesarean infant delivery | Pregnancy, puerperium and perinatal conditions | Non-systematic Assessment | Serious Adverse Events not resulting in death were not monitored/assessed in the control arm. |
|
| Anemia | Blood and lymphatic system disorders | Non-systematic Assessment | Serious Adverse Events not resulting in death were not monitored/assessed in the control arm. |
|
| Typhoid fever | Infections and infestations | Non-systematic Assessment | Serious Adverse Events not resulting in death were not monitored/assessed in the control arm. |
|
| Seizures | Nervous system disorders | Non-systematic Assessment | Serious Adverse Events not resulting in death were not monitored/assessed in the control arm. |
|
| Suspected bacterial or tubercular respiratory infection resulting in death | Infections and infestations | Non-systematic Assessment |
|
| Liver disease resulting in death | Hepatobiliary disorders | Non-systematic Assessment |
|
| Presumed sepsis resulting in death | Immune system disorders | Non-systematic Assessment |
|
| Respiratory failure resulting in death | Respiratory, thoracic and mediastinal disorders | Non-systematic Assessment |
|
| Hepatocellular carcinoma resulting in death | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-systematic Assessment |
|
| Death, cause unknown | General disorders | Non-systematic Assessment |
|
| Suspected tuberculosis resulting in death | Infections and infestations | Non-systematic Assessment |
|
| Severe anemia resulting in death | Blood and lymphatic system disorders | Non-systematic Assessment |
|
| AIDS resulting in death | Immune system disorders | Non-systematic Assessment |
|
| Kidney disease resulting in death | Renal and urinary disorders | Non-systematic Assessment |
|
| Sickle cell anemia resulting in death | Blood and lymphatic system disorders | Non-systematic Assessment |
|
| Severe malnutrition resulting in death | Metabolism and nutrition disorders | Non-systematic Assessment |
|
| Pulmonary tuberculosis resulting in death | Infections and infestations | Non-systematic Assessment |
|
| Organ failure, cause unknown, resulting in death | General disorders | Non-systematic Assessment |
|
| Threatened abortion | Pregnancy, puerperium and perinatal conditions | Non-systematic Assessment | Serious Adverse Events not resulting in death were not monitored/assessed in the control arm. |
|
| Encephalitis | Infections and infestations | Non-systematic Assessment | Serious Adverse Events not resulting in death were not monitored/assessed in the control arm. |
|
| CNS-TB with possible brain tumor resulting in death | Nervous system disorders | Non-systematic Assessment |
|
| Renal failure resulting in death | Renal and urinary disorders | Non-systematic Assessment |
|
| Abdominal tumor resulting in death | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-systematic Assessment |
|
| Pre-eclampsia toxemia resulting in death | Pregnancy, puerperium and perinatal conditions | Non-systematic Assessment |
|
| Kaposi sarcoma resulting in death | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-systematic Assessment |
|
| Pneumonia resulting in death | Infections and infestations | Non-systematic Assessment |
|
| Complications following Cesarean childbirth resulting in death | Pregnancy, puerperium and perinatal conditions | Non-systematic Assessment |
|
Not provided
Not provided
| AZT-3TC-NVP |
|
| TDF-3TC-ATV/r |
|
| AZT-3TC-ATV/r |
|
| ABC-3TC-EFV |
|
| Other |
|
| Re-engaging - started treatment > than 6 months before enrolment, no HIV care visit within 6 months |
|
|
|
|